Biosyent Stock Performance
BIOYF Stock | USD 8.43 0.09 1.06% |
On a scale of 0 to 100, Biosyent holds a performance score of 9. The firm shows a Beta (market volatility) of -0.0039, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Biosyent are expected to decrease at a much lower rate. During the bear market, Biosyent is likely to outperform the market. Please check Biosyent's treynor ratio, as well as the relationship between the semi variance and rate of daily change , to make a quick decision on whether Biosyent's price patterns will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Biosyent are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite nearly uncertain basic indicators, Biosyent may actually be approaching a critical reversion point that can send shares even higher in August 2025. ...more
Begin Period Cash Flow | 20.3 M | |
Total Cashflows From Investing Activities | -4.8 M |
Biosyent |
Biosyent Relative Risk vs. Return Landscape
If you would invest 753.00 in Biosyent on April 17, 2025 and sell it today you would earn a total of 90.00 from holding Biosyent or generate 11.95% return on investment over 90 days. Biosyent is currently producing 0.1985% returns and takes up 1.6579% volatility of returns over 90 trading days. Put another way, 14% of traded pink sheets are less volatile than Biosyent, and 96% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
Risk |
Biosyent Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biosyent's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Biosyent, and traders can use it to determine the average amount a Biosyent's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1197
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | BIOYF | |||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns |
Estimated Market Risk
1.66 actual daily | 14 86% of assets are more volatile |
Expected Return
0.2 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average Biosyent is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biosyent by adding it to a well-diversified portfolio.
Biosyent Fundamentals Growth
Biosyent Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Biosyent, and Biosyent fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biosyent Pink Sheet performance.
Return On Equity | 0.19 | |||
Return On Asset | 0.13 | |||
Profit Margin | 0.22 % | |||
Operating Margin | 0.29 % | |||
Current Valuation | 45.49 M | |||
Shares Outstanding | 12.1 M | |||
Price To Earning | 23.21 X | |||
Price To Book | 2.56 X | |||
Price To Sales | 2.27 X | |||
Revenue | 28.62 M | |||
EBITDA | 8.92 M | |||
Cash And Equivalents | 27.9 M | |||
Cash Per Share | 2.28 X | |||
Total Debt | 1.48 M | |||
Debt To Equity | 0.04 % | |||
Book Value Per Share | 2.71 X | |||
Cash Flow From Operations | 4.67 M | |||
Earnings Per Share | 0.36 X | |||
Total Asset | 37.17 M | |||
About Biosyent Performance
By analyzing Biosyent's fundamental ratios, stakeholders can gain valuable insights into Biosyent's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Biosyent has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Biosyent has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada. Biosyent operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.Things to note about Biosyent performance evaluation
Checking the ongoing alerts about Biosyent for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Biosyent help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.About 41.0% of the company shares are held by company insiders |
- Analyzing Biosyent's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biosyent's stock is overvalued or undervalued compared to its peers.
- Examining Biosyent's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biosyent's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biosyent's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biosyent's pink sheet. These opinions can provide insight into Biosyent's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Biosyent Pink Sheet analysis
When running Biosyent's price analysis, check to measure Biosyent's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biosyent is operating at the current time. Most of Biosyent's value examination focuses on studying past and present price action to predict the probability of Biosyent's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biosyent's price. Additionally, you may evaluate how the addition of Biosyent to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
CEOs Directory Screen CEOs from public companies around the world | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume |